Systematic Reviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 28, 2016; 8(9): 452-460
Published online Mar 28, 2016. doi: 10.4254/wjh.v8.i9.452
Comprehensive review of telbivudine in pregnant women with chronic hepatitis B
Teerha Piratvisuth, Guo Rong Han, Stanislas Pol, Yuhong Dong, Aldo Trylesinski
Teerha Piratvisuth, Department of Medicine, NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, Songkhla 90110, Thailand
Guo Rong Han, Department of Gynecology and Obstetrics, the Second Affiliated Hospital of the Southeast University, Nanjing 210003, Jiangsu Province, China
Stanislas Pol, Département d’Hépatologie, Inserm USM20, Institut Pasteur, AP-HP, hôpital Cochin, Université Paris Descartes, 75006 Paris, France
Yuhong Dong, Aldo Trylesinski, Novartis Pharma AG, 4056 Basel, Switzerland
Author contributions: Piratvisuth T, Han GR, Pol S, Dong Y and Trylesinski A contributed to the concept, inception, design, interpretation of data, and critical revision of the manuscript; Dong Y collected the data and performed the analysis; all authors approved the final version of the manuscript, including the authorship list.
Supported by Novartis Pharma AG.
Conflict-of-interest statement: Dr. Teerha Piratvisuth is an advisory board member of BMS, Roche, MSD and Novartis and has received fees for serving as a speaker for BMS, Roche, MSD, Novartis and GSK; he has received research grants from BMS, Roche, MSD, Novartis, Fibrogen and Bayer. Dr. Guo Rong Han has received fees for serving as a speaker for Novartis; Dr. Stanislas Pol has received fees for serving as a speaker for the following companies: GSK, BMS, Boehringer Ingelheim, Janssen, Gilead, Roche, MSD, Sanofi, Novartis, Vertex, and Abbvie; he has received grants from BMS, Gilead, Roche, and MSD and is also a board member of the following companies: GSK, BMS, Boehringer Ingelheim, Janssen, Gilead, Roche, MSD, Sanofi, Novartis, Vertex, and Abbvie. Dr. Aldo Trylesinski and Dr. Yuhong Dong are employees of Novartis.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Teerha Piratvisuth, MD, Department of Medicine, NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, 15 Equipment Acantholysis SOI Road, Hat Yai District, Songkhla 90110, Thailand. teerha.p@psu.ac.th
Telephone: +66-74-451966 Fax: +66-74-429436
Received: December 21, 2015
Peer-review started: December 22, 2015
First decision: January 20, 2016
Revised: February 22, 2016
Accepted: March 14, 2016
Article in press: March 16, 2016
Published online: March 28, 2016
Processing time: 93 Days and 15.8 Hours
Core Tip

Core tip: The data from literatures, pharmacovigilance reports on telbivudine exposure and antiretroviral pregnancy registry during pregnancy in women with hepatitis B virus (HBV) infection showed no increased rates of live birth defects, spontaneous abortion or elective termination. No fetal/neonatal toxicity was reported during telbivudine treatment. Telbivudine exposure in the second and/or third trimesters of pregnancy has been shown to reduce the risk of HBV transmission from mother to child if administered in addition to hepatitis B immunoglobulin and HBV vaccination with a favorable safety profile.